Role of HMGB1 in Temporomandibular Joint Osteoarthritis

doi:10.13701/j.cnki.kqyxyj.2020.12.005

Abstract

Abstract: High mobility group box-1 protein (HMGB1) is an architectural chromatin-binding protein that can be released actively by activated cells or passively by dying cells and can serve as a cytokine to drive the pathogenesis of inflammation. Temporomandibular joint osteoarthritis (TMJOA) is a common clinical disease, but so far, its pathogenesis is not yet clear. It has been confirmed that HMGB1 expression is increased in TMJOA tissues. Based on the biological characteristics of HMGB1, this article reviews the research progress of HMGB1 in TMJOA in order to provide new ideas for the treatment of TMJOA.

Key words: high mobility group box-1 protein, temporomandibular joint osteoarthritis, inflammation, pathway

HU Zhihui, FANG Wei. Role of HMGB1 in Temporomandibular Joint Osteoarthritis[J]. Journal of Oral Science Research, 2020, 36(12): 1099-1102.

References

[1] Wang XD, Zhang JN, Gan YH, et al. Current understanding of pathogenesis and treatment of TMJ osteoarthritis [J]. J Dent Res, 2015, 94(5): 666-673.
[2] Feng Y, Fang W, Li C, et al. The expression of high-mobility group box protein-1 in temporomandibular joint osteoarthritis with disc perforation [J]. J Oral Pathol Med, 2016, 45(2): 148-152.
[3] Goodwin GH, Johns EW. Isolation and characterisation of two calf-thymus chromatin non-histone proteins with high contents of acidic and basic amino acids [J]. Eur J Biochem, 1973, 40(1): 215-219.
[4] Wang H, Bloom O, Zhang M, et al. HMG-1 as a late mediator of endotoxin lethality in mice [J]. Science, 1999, 285(5425): 248-251.
[5] Bonaldi T, Talamo F, Scaffidi P, et al. Monocytic cells hyperacetylate chromatin protein HMGB1 to redirect it towards secretion [J]. EMBO J, 2003, 22(20): 5551-5560.
[6] Andersson U, Yang H,Harris H. High-mobility group box 1 protein (HMGB1) operates as an alarmin outside as well as inside cells [J]. Semin Immunol, 2018, 38: 40-48.
[7] Tang Y, Zhao X, Antoine D, et al. Regulation of posttranslational modifications of HMGB1 during immune responses [J]. Antioxid Redox Signal, 2016, 24(12): 620-634.
[8] Harris HE, Andersson U, Pisetsky DS.HMGB1: a multifunctional alarmin driving autoimmune and inflammatory disease [J]. Nat Rev Rheumatol, 2012, 8(4): 195-202.
[9] Scaffidi P, Misteli T, Bianchi ME. Release of chromatin protein HMGB1 by necrotic cells triggers inflammation [J]. Nature, 2002, 418(6894): 191-195.
[10] Ito I, Fukazawa J, Yoshida M. Post-translational methylation of high mobility group box 1 (HMGB1) causes its cytoplasmic localization in neutrophils [J]. J Biol Chem, 2007, 282(22): 16336-16344.
[11] Gardella S, Andrei C, Ferrera D, et al. The nuclear protein HMGB1 is secreted by monocytes via a non-classical, vesicle-mediated secretory pathway [J]. EMBO Rep, 2002, 3(10): 995-1001.
[12] Pellegrini L, Foglio E, Pontemezzo E, et al. HMGB1 and repair: focus on the heart [J]. Pharmacol Ther, 2019, 196: 160-182.
[13] Andersson U, Yang H,Harris H. Extracellular HMGB1 as a therapeutic target in inflammatory diseases [J]. Expert Opin Ther Targets, 2018, 22(3): 263-277.
[14] Bell CW, Jiang W, Reich CF, et al. The extracellular release of HMGB1 during apoptotic cell death [J]. Am J Physiol Cell Physiol, 2006, 291(6): C1318-C1325.
[15] Kazama H, Ricci JE, Herndon JM, et al. Induction of immunological tolerance by apoptotic cells requires caspase-dependent oxidation of high-mobility group box-1 protein [J]. Immunity, 2008, 29(1): 21-32.
[16] Deng M, Scott MJ, Fan J, et al. Location is the key to function: HMGB1 in sepsis and trauma-induced inflammation [J]. J Leukoc Biol, 2019, 106(1): 161-169.
[17] Stark K, Philippi V, Stockhausen S, et al. Disulfide HMGB1 derived from platelets coordinates venous thrombosis in mice [J]. Blood, 2016, 128(20): 2435-2449.
[18] Bianchi ME. HMGB1 loves company [J]. J Leukoc Biol, 2009, 86(3): 573-576.
[19] Thorburn J, Frankel AE, Thorburn A. Regulation of HMGB1 release by autophagy [J]. Autophagy, 2009, 5(2): 247-249.
[20] Venereau E, Casalgrandi M, Schiraldi M, et al.Mutually exclusive redox forms of HMGB1 promote cell recruitment or proinflammatory cytokine release [J]. J Exp Med, 2012, 209(9): 1519-1528.
[21] Yang H, Wang H,Andersson U. Targeting Inflammation Driven by HMGB1 [J]. Front Immunol, 2020, 11: 484.
[22] Paudel YN, Angelopoulou E, Piperi C, et al. Enlightening the role of high mobility group box 1 (HMGB1) in inflammation: Updates on receptor signalling [J]. Eur J Pharmacol, 2019, 858: 172487.
[23] Riuzzi F, Sorci G, Sagheddu R, et al. RAGE in the pathophysiology of skeletal muscle [J]. J Cachexia Sarcopenia Muscle, 2018, 9(7): 1213-1234.
[24] Alam SI, Rehman SU, Kim MO. Nicotinamide improves functional recovery via regulation of the RAGE/JNK/NF-kappaB signaling pathway after brain injury [J]. J Clin Med, 2019, 8(2).
[25] Tripathi A, Shrinet K,Kumar A. HMGB1 protein as a novel target for cancer [J]. Toxicol Rep, 2019, 6: 253-261.
[26] Beutler B. TLR4 as the mammalian endotoxin sensor [J]. Curr Top Microbiol Immunol, 2002, 270: 109-120.
[27] Visintin A, Iliev DB, Monks BG, et al. MD-2 [J]. Immunobiology, 2006, 211(6-8): 437-447.
[28] Park BS, Song DH, Kim HM, et al.The structural basis of lipopolysaccharide recognition by the TLR4-MD-2 complex [J]. Nature, 2009, 458(7242): 1191-1195.
[29] Yang H, Wang H, Ju Z, et al. MD-2 is required for disulfide HMGB1-dependent TLR4 signaling [J]. J Exp Med, 2015, 212(1): 5-14.
[30] Meng L, Li L, Lu S, et al. The protective effect of dexmedetomidine on LPS-induced acute lung injury through the HMGB1-mediated TLR4/NF-kappaB and PI3K/Akt/mTOR pathways [J]. Mol Immunol, 2018, 94: 7-17.
[31] Fu Y, Lei J, Zhuang Y, et al. Overexpression of HMGB1 A-box reduced IL-1beta-induced MMP expression and the production of inflammatory mediators in human chondrocytes [J]. Exp Cell Res, 2016, 349(1): 184-190.
[32] Biscetti F, Flex A, Pecorini G, et al. The role of high-mobility group box protein 1 in collagen antibody-induced arthritis is dependent on vascular endothelial growth factor [J]. Clin Exp Immunol, 2016, 184(1): 62-72.
[33] Sun XH, Liu Y, Han Y, et al. Expression and significance of high-mobility group protein B1 (HMGB1) and the receptor for advanced glycation end-product (RAGE) in knee osteoarthritis [J]. Med Sci Monit, 2016, 22: 2105-2112.
[34] Amin AR, Islam AB. Genomic analysis and differential expression of HMG and S100A family in human arthritis: upregulated expression of chemokines, IL-8 and nitric oxide by HMGB1 [J]. DNA Cell Biol, 2014, 33(8): 550-565.
[35] Ke X, Jin G, Yang Y, et al. Synovial fluid HMGB-1 levels are associated with osteoarthritis severity [J]. Clin Lab, 2015, 61(7): 809-818.
[36] Garcia-Arnandis I, Guillen MI, Castejon MA, et al. Haem oxygenase-1 down-regulates high mobility group box 1 and matrix metalloproteinases in osteoarthritic synoviocytes [J]. Rheumatology (Oxford), 2010, 49(5): 854-861.
[37] Terada C, Yoshida A, Nasu Y, et al. Gene expression and localization of high-mobility group box chromosomal protein-1 (HMGB-1)in human osteoarthritic cartilage [J]. Acta Med Okayama, 2011, 65(6): 369-377.
[38] Loeser RF, Yammani RR, Carlson CS, et al. Articular chondrocytes express the receptor for advanced glycation end products: Potential role in osteoarthritis [J]. Arthritis Rheum, 2005, 52(8): 2376-2385.
[39] Garcia-Arnandis I, Guillen MI, Gomar F, et al. High mobility group box 1 potentiates the pro-inflammatory effects of interleukin-1beta in osteoarthritic synoviocytes [J]. Arthritis Res Ther, 2010, 12(4): R165.
[40] Wahamaa H, Schierbeck H, Hreggvidsdottir HS, et al. High mobility group box protein 1 in complex with lipopolysaccharide or IL-1 promotes an increased inflammatory phenotype in synovial fibroblasts [J]. Arthritis Res Ther, 2011, 13(4): R136.
[41] Li C, Cai H, Meng Q, et al. IL-1beta mediating high mobility group box protein-1 expression in condylar chondrocyte during temporomandibular joint inflammation [J]. J Oral Pathol Med, 2016, 45(7): 539-545.
[42] Feng Y, Ke J, Cao P, et al. HMGB1-induced angiogenesis in perforated disc cells of human temporomandibular joint [J]. J Cell Mol Med, 2018, 22(2): 1283-1291.
[43] Khan MI, Rath S, Adhami VM, et al.Hypoxia driven glycation: Mechanisms and therapeutic opportunities [J]. Semin Cancer Biol, 2018, 49: 75-82.